LL-37 is a naturally occurring antimicrobial peptide produced by human immune cells and skin, part of the innate immune system’s first line of defense against infection — a well-established biological role that’s generated interest in whether applying additional LL-37 topically could improve wound healing, particularly in chronic, slow-healing wounds.

The Antimicrobial Research Is Solid

LL-37’s role in disrupting bacterial membranes and modulating local immune response at the skin barrier is well-documented basic science, studied for decades as part of innate immunity research.

“The basic immunology is rock solid. The specific question — does adding more of it externally speed up healing — is still being actively researched, not settled.”

— a dermatology researcher who studies antimicrobial peptides in wound care

The Wound-Healing Question Is Newer and Less Settled

Research specifically testing LL-37 as a topical wound-healing agent is earlier-stage and more mixed, with some preclinical studies showing benefit and open questions remaining about optimal concentration and delivery — a genuinely active but unresolved research area, not a settled clinical application.

Why More Isn’t Automatically Better

Because LL-37 is part of an immune signaling system, its concentration-dependent effects aren’t necessarily linear — some research suggests effects can shift or even reverse at different concentrations, which complicates the simple “more equals better healing” framing in marketing.